Literature DB >> 929037

[Abnormal movements caused by L-DOPA in patients with Parkinson's disease: correlation with the plasma concentrations of DOPA and O-methyl-DOPA].

F Lhermitte, Y Agid, C Feuerstein, F Serre, J L Signoret, J M Studler, A M Bonnet.   

Abstract

This study involved twleve parkinsonian patients exposed to abnormal movements provoked by L-DOPA. Including six patients with "mid-dose" dyskinesias and six others with "onset and end of dose" dyskinesias, Correlation between the circumstances of onset of abnormal movements and plasma concentrations of DOPA and O-methyl-DOPA, after administration of a dose of L-DOPA + IDC, gave the following results: 1) mid-dose dyskinesias appeared with the highest plasma concentrations of DOPA, at the maximum therapeutic effect; 2) onset and end of dose occurred during rise and fall in plasma levels of DOPA, coinciding with the relief and the reappearance of parkinsonian symptoms respectively; 3) no correlation could be established between plasma concentrations of O-methyl-DOPA and the duration of the period of clinical remission or of abnormal movements. These biochemical data, completed by the neuropharmacological study of one patient with onset and end of dose abnormal movements suggest the predominant role of a disturbance in central dopaminergic mechanisms in the genesis of abnormal movements, whatever their nature.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 929037

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  4 in total

Review 1.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

2.  Long-term treatment of Parkinson's disease with bromocriptine.

Authors:  A Rascol; B Guiraud; J L Montastruc; J David; M Clanet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-02       Impact factor: 10.154

3.  Effects of tiapride in tardive dyskinesia.

Authors:  P Pollak; J M Gaio; M Hommel; J Pellat; J Perret
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

4.  Which factors predict cognitive decline in Parkinson's disease?

Authors:  D Caparros-Lefebvre; N Pécheux; V Petit; A Duhamel; H Petit
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-01       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.